Since the presence of tumor-infiltrating B cells was usually correlated to better overall survival and treatment outcomes, we selected several representative B-cell signatures (CD79A, MS4A1, IGHD, and FCRL4) and examined their prognostic values in NPC patients. This evidence concerns the gene FCRL4 and neoplasm.